Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104390 · ClinicalTrials.gov registry record · Phase 1
Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing
A Phase 1 study of Type I Hypersensitivity, sponsored by Allergy Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00104390: Completed Phase 1 study of Type I Hypersensitivity, sponsored by Allergy Therapeutics.
NCT00104390 is a Phase 1 study of Type I Hypersensitivity that has completed, run by Allergy Therapeutics. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00104390, a Phase 1 study of Type I Hypersensitivity, has completed, sponsored by Allergy Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the residual allergenicity of Grass MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing. This is done by a comparison of the wheal response after skin prick testing with aqueous native and modified allergen, modified tyrosine adsorbed allergen and Grass MATA MPL (modified tyrosine adsorbed + MPL).
Conditions Studied
Interventions
- BIOLOGICAL Grass MATA MPL
Study Locations (1)
Oregon
- Allergy Associates Research Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-04 |
| Phase | Phase 1 |
What the finished NCT00104390 record still lists
NCT00104390 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Type I Hypersensitivity appearing as the primary indexed condition, and to 1 intervention - of which Grass MATA MPL is the first listed.
NCT00104390 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT00104390 about?
NCT00104390 is a clinical study titled "Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing". The purpose of this study is to evaluate the residual allergenicity of Grass MATA (modified pollen allergen tyrosine adsorbate) by skin prick testing. This is done by a comparison of the wheal response after skin prick testing with aqueous native and modified allergen, modified tyrosine adsorbed all...
What is the current status of trial NCT00104390?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2005-03. Estimated completion is 2005-04.
What conditions does trial NCT00104390 study?
This clinical trial studies the following conditions: Type I Hypersensitivity.
What interventions are being tested in trial NCT00104390?
The interventions under investigation include: Grass MATA MPL (BIOLOGICAL).
Who is sponsoring clinical trial NCT00104390?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00104390 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type I Hypersensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00104390's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia